Fundraising Fox
/People
Sign in

David Schenkein

Investor

General Partner at GV (Google Ventures)

Boston, Massachusetts

Writes $250K – $50M checks · typically $25M

Find your path to David

Sign up to see every warm intro you have to David

  • Paths you didn't know you had: your email and LinkedIn already hold routes to David. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

About

David Schenkein is a physician-investor, founding Agios CEO who oversaw metabolism‑targeting AML drug approvals, now a general partner who remains a clinician and warns non-dilutive deals can be more dilutive.

Likely emails· guessed from name + firm domain, not firm-published

Invests in

AI & Machine LearningBiotechConsumerDigital HealthEnterprise SoftwareHealthtechMedical Devices

Beyond investing

Education
Studied at State University of New York Upstate Medical University (Doctor of Medicine (M.D.), 1983) Studied at Wesleyan University (Bachelor of Arts (B.A.), Chemistry, 1979)

Mentioned above: the Wesleyan University mafia →

From published sources — common ground for a warm intro.

Deals · 2

Treeline BiosciencesBoard seat

via GV (Google Ventures) · filed Sep 2025 · $250M raise

Denali TherapeuticsBoard seat

via GV (Google Ventures) · filed Mar 2024 · $499.7M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Aera TherapeuticsAgios Pharmaceuticalsbluebird bioLeyden LabsPrime MedicineRegeneron

Sources: the firm's website · curated public sources · SEC Form D filings.

Colleagues at GV (Google Ventures)

Abi Joyce
Executive Business Partner at GV (Google Ventures)
Amy Anton
Talent Partner at GV (Google Ventures)
Anika Gupta
Investor at GV (Google Ventures)
Anthony Philippakis
Investor at GV (Google Ventures)
Araceli Pacheco
Sr. Financial Analyst at GV (Google Ventures)
Ben Robbins
Investor at GV (Google Ventures)
Brendan Bulik-Sullivan
Investor at GV (Google Ventures)
Caleb Langlinais
Financial Analyst at GV (Google Ventures)

Network12

David KraneScout
CEO & Managing Partner at GV (Google Ventures)
Erik NordlanderScout
Investor at GV (Google Ventures)
Graham SpencerScout
General Partner at GV (Google Ventures)
Lo ToneyScout
Founding Managing Partner at Plexo Capital
M.G. SieglerScout
General Partner at GV (Google Ventures)
Andrew Wheeler
General Partner at GV (Google Ventures)
Anthony Philippakis
Investor at GV (Google Ventures)
Arie Belldegrun
Founder and Senior Managing Director at Vida Ventures
Ben Robbins
Investor at GV (Google Ventures)
Blake Byers
General Partner at GV (Google Ventures)
Braden Kowitz
Investor at GV (Google Ventures)
Eli Casdin
Chief Investment Officer and Founder at Casdin Capital

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Schenkein?
David Schenkein is a physician-investor, founding Agios CEO who oversaw metabolism‑targeting AML drug approvals, now a general partner who remains a clinician and warns non-dilutive deals can be more dilutive.
Where does David Schenkein work?
David Schenkein is General Partner at GV (Google Ventures).
What does David Schenkein invest in?
David Schenkein invests in AI & Machine Learning, Biotech, Consumer, Digital Health, Enterprise Software, Healthtech, Medical Devices.
What check size does David Schenkein write?
David Schenkein typically writes checks of $250K – $50M.
What boards does David Schenkein sit on?
David Schenkein holds tracked board seats at Aera Therapeutics, Agios Pharmaceuticals, bluebird bio, Denali Therapeutics, Denali Therapeutics, Leyden Labs, Prime Medicine, Regeneron, Treeline Biosciences, Treeline Biosciences.
What companies has David Schenkein invested in?
Investments tracked here include Accent Therapeutics, Aera Therapeutics, Arda Therapeutics, Cerevance, Delphia Therapeutics, Denali Therapeutics, Encoded Therapeutics, Epi Biologics, IconOVir Bio, Kronos Bio, Leyden Labs, Mestag, and 11 more.

Founder mafias

Upstate Medical University mafia3

Also came through, then founded or led a company.

Jawad ArshadDoctor of Medicine (MD)Founded Zipy +1Brian FenglerMDFounded EvidenceCare

Treeline Biosciences mafia2

Also came through, then founded or led a company.

Kristina BurowDirectorFounded Neumora Therapeutics

About this profile. Compiled from public sources — GV (Google Ventures)'s own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights